Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 4/20 | 0.39 |
| ▸ | AXL | P30530 | 2/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | ULK1 | O75385 | 1/20 | 0.37 |
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | ARHGDIA | P52565 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5409805 | 1.00 | PIM1 (0.40) | PIM1NOS1AXLROCK1MCHR1 | |
| SCHEMBL5419690 | 1.00 | PIM1 (0.40) | PIM1NOS1AXLROCK1MCHR1 | |
| SCHEMBL5419689 | 1.00 | PIM1 (0.40) | PIM1NOS1AXLROCK1MCHR1 | |
| SCHEMBL5409811 | 1.00 | PIM1 (0.40) | PIM1NOS1AXLROCK1MCHR1 | |
| Hydrochloric Acid SCHEMBL5414945 | 0.99 | PIM1 (0.40) | PIM1NOS1AXLROCK1MCHR1 | |
| Hydrochloric Acid SCHEMBL5414941 | 0.99 | PIM1 (0.40) | PIM1NOS1AXLROCK1MCHR1 | |
| Hydrochloric Acid SCHEMBL5414940 | 0.99 | PIM1 (0.40) | PIM1NOS1AXLROCK1MCHR1 | |
| SCHEMBL5423886 | 0.83 | NOS1 (0.42) | PIM1NOS1AXLROCK1MCHR1 | |
| SCHEMBL5409819 | 0.83 | NOS1 (0.42) | PIM1NOS1AXLROCK1MCHR1 | |
| SCHEMBL5409826 | 0.83 | NOS1 (0.42) | PIM1NOS1AXLROCK1MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20040138286-A1 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1403255-A1 | Rho KINASE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138286-A1 | Rho kinase inhibitors | ROCK1, ROCK2, ARHGDIA | PIM1 760/4885NOS1 131/4885AXL 1805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.